Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$22.56 +0.0%	$21.58	$13.40 ▼ $25.23	$3.77B	0.64	1.97 million shs	1.52 million shs
ARWR Arrowhead Pharmaceuticals	$16.76 -11.1%	$16.34	$9.57 ▼ $29.86	$2.60B	0.93	1.58 million shs	3.01 million shs
ASND Ascendis Pharma A/S	$169.90 -4.1%	$169.61	$111.09 ▼ $183.00	$10.83B	0.38	506,841 shs	617,646 shs
IONS Ionis Pharmaceuticals	$41.76 -1.0%	$37.30	$23.95 ▼ $52.34	$6.71B	0.23	1.62 million shs	1.27 million shs
RARE Ultragenyx Pharmaceutical	$26.31 -4.0%	$35.65	$26.00 ▼ $60.37	$2.59B	0.26	976,201 shs	3.90 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+2.22%	-1.10%	+53.09%	+22.89%
ARWR Arrowhead Pharmaceuticals	+3.01%	-0.05%	+21.61%	+67.70%	-32.73%
ASND Ascendis Pharma A/S	+1.03%	+0.40%	+2.49%	+7.36%	+27.88%
IONS Ionis Pharmaceuticals	-1.40%	-0.50%	+16.65%	+48.49%	-12.07%
RARE Ultragenyx Pharmaceutical	+0.37%	-11.67%	-25.23%	-23.20%	-37.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.9843 of 5 stars	3.4	3.0	0.0	2.0	4.2	2.5
ARWR Arrowhead Pharmaceuticals	3.8607 of 5 stars	3.4	2.0	3.4	3.7	1.7	0.0
ASND Ascendis Pharma A/S	3.6293 of 5 stars	4.5	3.0	0.0	2.9	1.7	0.6
IONS Ionis Pharmaceuticals	4.4693 of 5 stars	4.4	2.0	3.0	2.1	3.3	0.6
RARE Ultragenyx Pharmaceutical	4.3772 of 5 stars	4.5	1.0	3.8	2.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$27.88	23.56% Upside
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	160.83% Upside
ASND Ascendis Pharma A/S	3.00	Buy	$223.07	31.29% Upside
IONS Ionis Pharmaceuticals	2.76	Moderate Buy	$57.13	36.81% Upside
RARE Ultragenyx Pharmaceutical	2.93	Moderate Buy	$83.64	217.91% Upside

Current Analyst Ratings Breakdown

Latest ARWR, ACAD, ASND, IONS, and RARE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	RARE Ultragenyx Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$35.00 ➝ $34.00
7/14/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$65.00 ➝ $55.00
7/11/2025	ASND Ascendis Pharma A/S	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$213.00 ➝ $243.00
7/10/2025	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$88.00 ➝ $65.00
7/3/2025	ASND Ascendis Pharma A/S	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$250.00
7/1/2025	IONS Ionis Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$51.00 ➝ $57.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/26/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.94	$0.71 per share	31.99	$4.40 per share	5.13
ARWR Arrowhead Pharmaceuticals	$3.55M	651.99	N/A	N/A	$1.54 per share	10.88
ASND Ascendis Pharma A/S	$393.54M	26.39	N/A	N/A	($1.88) per share	-90.37
IONS Ionis Pharmaceuticals	$705M	9.43	N/A	N/A	$3.73 per share	11.20
RARE Ultragenyx Pharmaceutical	$560.23M	4.44	N/A	N/A	$2.76 per share	9.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	16.47	29.68	4.86	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	22.17	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
ASND Ascendis Pharma A/S	-$409.12M	-$6.28	N/A	707.92	N/A	-93.22%	N/A	-33.29%	9/2/2025 (Estimated)
IONS Ionis Pharmaceuticals	-$453.90M	-$2.99	N/A	N/A	N/A	-63.65%	-91.85%	-15.77%	7/30/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.88	N/A	N/A	N/A	-93.04%	-186.49%	-36.81%	7/30/2025 (Estimated)

Latest ARWR, ACAD, ASND, IONS, and RARE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	RARE Ultragenyx Pharmaceutical	-$1.27	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	N/A	N/A	N/A	$263.07 million	N/A
7/30/2025	Q2 2025	IONS Ionis Pharmaceuticals	$0.19	N/A	N/A	N/A	$270.90 million	N/A
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/6/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.54	-$1.57	-$0.03	-$1.57	$145.98 million	$139.29 million
5/1/2025	Q1 2025	ASND Ascendis Pharma A/S	-$1.56	-$1.66	-$0.10	-$1.66	$98.56 million	$123.97 million
4/30/2025	Q1 2025	IONS Ionis Pharmaceuticals	-$1.07	-$0.93	+$0.14	-$0.93	$144.31 million	$132.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
ASND Ascendis Pharma A/S	N/A	1.04	0.71
IONS Ionis Pharmaceuticals	2.63	9.66	9.62
RARE Ultragenyx Pharmaceutical	N/A	2.40	2.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ARWR Arrowhead Pharmaceuticals	62.61%
ASND Ascendis Pharma A/S	N/A
IONS Ionis Pharmaceuticals	93.86%
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
ARWR Arrowhead Pharmaceuticals	4.30%
ASND Ascendis Pharma A/S	40.00%
IONS Ionis Pharmaceuticals	2.60%
RARE Ultragenyx Pharmaceutical	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	123.01 million	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
ASND Ascendis Pharma A/S	1,017	61.13 million	36.68 million	Optionable
IONS Ionis Pharmaceuticals	1,069	159.16 million	155.02 million	Optionable
RARE Ultragenyx Pharmaceutical	1,294	94.54 million	89.34 million	Optionable

ARWR, ACAD, ASND, IONS, and RARE Headlines

Recent News About These Companies

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 18 at 4:30 PM | globenewswire.com

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. ...

July 18 at 4:12 PM | gurufocus.com

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm

July 18 at 3:07 PM | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

July 18 at 12:00 PM | globenewswire.com

Wedbush Brokers Decrease Earnings Estimates for RARE

July 18 at 2:57 AM | americanbankingnews.com

Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE)

July 17 at 11:53 AM | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

July 17 at 10:00 AM | prnewswire.com

Wedbush Equities Analysts Reduce Earnings Estimates for RARE

July 17 at 7:16 AM | marketbeat.com

William Blair Issues Negative Forecast for RARE Earnings

July 17 at 4:54 AM | americanbankingnews.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Lowered by Bank of New York Mellon Corp

July 17 at 3:32 AM | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Down 5.7% on Analyst Downgrade

July 17 at 2:27 AM | americanbankingnews.com

FDA rejects Ultragenyx gene therapy over manufacturing concerns

July 16 at 8:33 PM | biopharmadive.comB

William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE)

July 16 at 10:43 AM | insidermonkey.com

FY2025 EPS Estimates for RARE Cut by Cantor Fitzgerald

July 16 at 6:46 AM | marketbeat.com

William Blair Has Bearish Estimate for RARE FY2025 Earnings

July 16 at 6:46 AM | marketbeat.com

Wedbush Analysts Decrease Earnings Estimates for RARE

July 16 at 6:25 AM | marketbeat.com

Morgan Stanley Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

July 16 at 4:09 AM | americanbankingnews.com

Ultragenyx hit again, this time with a CRL in rare disease

July 15 at 10:19 PM | bioworld.comB

Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA

July 15 at 10:19 PM | msn.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading Down 5.7% on Analyst Downgrade

July 15 at 11:57 AM | marketbeat.com

Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA

July 15 at 9:31 AM | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
By Thomas Hughes | June 26, 2025
View Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
2 Under the Radar Space & Defense Stocks With Huge Potential
By Leo Miller | July 1, 2025
View 2 Under the Radar Space & Defense Stocks With Huge Potential
3 Stocks to Buy Ahead of the Upcoming Earnings Season
By Chris Markoch | July 11, 2025
View 3 Stocks to Buy Ahead of the Upcoming Earnings Season
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
By Gabriel Osorio-Mazilli | July 15, 2025
View Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters

ARWR, ACAD, ASND, IONS, and RARE Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$22.56 +0.01 (+0.04%)

Closing price 04:00 PM Eastern

Extended Trading

$22.44 -0.12 (-0.53%)

As of 06:58 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.76 -2.09 (-11.09%)

Closing price 04:00 PM Eastern

Extended Trading

$16.86 +0.10 (+0.60%)

As of 07:54 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Ascendis Pharma A/S NASDAQ:ASND

$169.90 -7.30 (-4.12%)

Closing price 04:00 PM Eastern

Extended Trading

$171.00 +1.10 (+0.65%)

As of 06:42 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ionis Pharmaceuticals NASDAQ:IONS

$41.76 -0.41 (-0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$41.76 +0.01 (+0.01%)

As of 04:10 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Ultragenyx Pharmaceutical NASDAQ:RARE

$26.31 -1.10 (-4.01%)

Closing price 04:00 PM Eastern

Extended Trading

$26.20 -0.11 (-0.42%)

As of 07:56 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time